XDH and gout: The evidence that urate-lowering treatment with xanthine oxidase inhibitors is able to blunt the progression of arterial stiffness in patients with gout, elevated SUA levels, and moderate to high cardiovascular risk profile [35] further supports the hypothesis that uric acid may determine plaque vulnerability and subsequent rupture.